+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and Executive Guides

  • ID: 5441818
  • Report
  • May 2022
  • Region: Global
  • 533 Pages
  • Howe Sound Research
The COVID-19 Pandemic Drives Point of Care Diagnostics into Hypergrowth

FEATURED COMPANIES

  • Abacus Diagnostica
  • Bio-Rad Laboratories, Inc
  • Eurofins Scientific
  • Immunexpress
  • Meridian Bioscience
  • Qiagen Gmbh
The COVID-19 pandemic is ushering in a new world of point of care diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician’s Office or even the Home? How much Covid-19 testing is being done at the Point of Care?

Point of Care testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

The report includes five year market forecasts.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abacus Diagnostica
  • Bio-Rad Laboratories, Inc
  • Eurofins Scientific
  • Immunexpress
  • Meridian Bioscience
  • Qiagen Gmbh

1 Market Guides
1.1 Molecular Diagnostics at the Point of Care - Strategic Situation Analysis and Impact of COVID-19
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors


2 Introduction and Market Definition
2.1 What are Molecular Diagnostics at the Point of Care?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.3.1 Revenues
2.4 Methodology
2.4.1 Authors
2.4.2 Sources
2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics


3 The Infectious Diseases - Market Analysis by Disease
3.1 HIV - Human Immunodeficiency Virus (AIDS)
3.1.1 Virology
3.1.1.1 Classification
3.1.1.2 Structure and genome
3.1.1.3 Tropism
3.1.1.4 Replication cycle
3.1.1.5 Genetic variability
3.1.2 Diagnosis
3.1.3 Testing
3.1.3.1 Antibody tests
3.1.3.2 Point of Care Tests (POCT)
3.1.3.3 Antigen Tests
3.1.3.4 Nucleic acid-based tests (NAT)
3.1.3.5 Other tests used in HIV treatment
3.1.4 Market Opportunity Analysis
3.2 HBV - Hepatitis B
3.2.1 Virology
3.2.1.1 Genome
3.2.1.2 Pathogenesis
3.2.1.3 Hepatitis B virus replication
3.2.1.4 Serotypes and genotypes
3.2.2 Mechanisms
3.2.3 Diagnosis
3.2.4 Market Opportunity Analysis
3.3 HCV - Hepatitis C
3.3.1 Taxonomy
3.3.2 Structure
3.3.2.1 Genome
3.3.3 Molecular biology
3.3.4 Replication
3.3.5 Genotypes
3.3.5.1 Clinical importance
3.3.6 Market Opportunity Analysis
3.4 HPV - Human papillomavirus
3.4.1 Virology
3.4.1.1 E6/E7 proteins
3.4.1.2 Role in cancer
3.4.1.3 E2 research
3.4.1.4 Latency period
3.4.1.5 Clearance
3.4.2 Diagnosis
3.4.2.1 Cervical testing
3.4.2.2 Oral testing
3.4.2.3 Testing men
3.4.2.4 Other testing
3.4.3 Market Opportunity Analysis
3.5 Influenza
3.5.1 Virology
3.5.1.1 Types of virus
3.5.1.2 Influenzavirus A
3.5.1.3 Influenzavirus B
3.5.1.4 Influenzavirus C
3.5.1.5 Structure, properties, and subtype nomenclature
3.5.1.6 Replication
3.5.2 Testing
3.5.2.1 Advantages/Disadvantages of Molecular Assays
3.5.3 Market Opportunity Analysis
3.6 CTGC - Chlamydia/Gonorhea
3.6.1 Gonorrhea
3.6.1.1 Diagnosis
3.6.1.2 Screening
3.6.2 Chlamydia
3.6.2.1 Diagnosis
3.6.2.2 Screening
3.6.3 Testing
3.6.3.1 Nucleic acid amplification tests (NAATs)
3.6.3.2 Performance of NAAT Tests
3.6.4 Market Opportunity Analysis
3.7 Tuberculosis
3.7.1 Mycobacteria
3.7.2 Diagnosis
3.7.2.1 Active tuberculosis
3.7.2.2 Latent tuberculosis
3.7.3 Epidemiology
3.7.4 Molecular Diagnostic Tests
3.7.5 Market Opportunity Analysis
3.8 MRSA - Methicillin-resistant Staphylococcus aureus
3.8.1 Diagnosis
3.8.2 FDA Approved Molecular Tests
3.8.3 Market Opportunity Analysis
3.9 VRE - Vancomycin-resistant Enterococcus
3.9.1 FDA Approved MDx Tests for VRE
3.9.2 Market Opportunity Analysis
3.10 Blood Screening
3.10.1 Collection and Testing
3.10.2 FDA Approved Multiplex Assays
3.10.3 Market Opportunity Analysis
3.11 COVID-19
3.11.1 Signs and symptoms
3.11.2 Transmission
3.11.3 Diagnosis
3.11.4 Prevention
3.11.5 Management
3.11.6 Prognosis
3.12 Pandemic Diagnostics
3.12.1 Risk Management - Spark and Spread
3.12.2 Dx Technology - Nucleic Acid-Based
3.12.3 Dx Technology - Immunoassay & Serology
3.12.4 Time to Market and Preparedness Issues
3.12.5 Unrecognized Role of Multiplex in Pandemic Management


4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Distributor and Reagent Supplier
4.1.5 Independent Testing Lab
4.1.6 Public National/regional lab
4.1.7 Hospital lab
4.1.8 Physician Office Labs and Clinics
4.1.9 Audit Body
4.1.10 Certification Body
4.2 The Clinical Laboratory Market Segments
4.2.1 Traditional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.3 Industry Structure
4.3.1 Hospital Testing Share
4.3.2 Economies of Scale
4.3.2.1 Hospital vs. Central Lab
4.3.3 Physician Office Lab’s
4.3.4 Physician’s and POCT


5 Profiles of Key MDx Companies
5.1 Abacus Diagnostica
5.2 Abbott Diagnostics
5.3 Accelerate Diagnostics
5.4 Ador Diagnostics
5.5 Akonni Biosystems
5.6 Alveo Technologies
5.7 Applied BioCode
5.8 Aus Diagnostics
5.9 Beckman Coulter Diagnostics
5.10 Becton, Dickinson and Company
5.11 Binx Health
5.12 Biocartis
5.13 bioMérieux Diagnostics
5.14 Bio-Rad Laboratories, Inc
5.15 Bosch Healthcare Solutions GmbH
5.16 Cepheid (now Danaher)
5.17 Chembio
5.18 Co Diagnostics
5.19 Credo Diagnostics Biomedical
5.20 Cue Health
5.21 Curetis N.V. / Curetis GmbH
5.22 Diagenode Diagnostics
5.23 Diascopic
5.24 Diasorin S.p.A
5.25 Eiken Chemical
5.26 Enzo Life Sciences, Inc
5.27 Eurofins Scientific
5.28 Fluxergy
5.29 Fulgent Genetics
5.30 Fusion Genomics
5.31 Genedrive
5.32 Genetic Signatures
5.33 GenMark Dx
5.34 Grifols
5.35 Hibergene Diagnostics
5.36 Hologic
5.37 Illumina
5.38 Immunexpress
5.39 Inflammatix
5.40 Invetech
5.41 Janssen Diagnostics
5.42 Karius
5.43 Lexagene
5.44 LightDeck Diagnostics
5.45 Luminex Corp
5.46 Lumos Diagnostics
5.47 Mammoth Biosciences
5.48 Maxim Biomedical
5.49 Meridian Bioscience
5.50 Mesa Biotech
5.51 Millipore Sigma
5.52 Mindray
5.53 Mobidiag
5.54 Nanomix
5.55 Operon
5.56 Oxford Nanopore Technologies
5.57 Panagene
5.58 Perkin Elmer
5.59 Primerdesign
5.60 Prominex
5.61 Qiagen Gmbh
5.62 Quantumdx
5.63 Quidel
5.64 Roche Molecular Diagnostics
5.65 Saw Diagnostics
5.66 Seegene
5.67 Siemens Healthineers
5.68 Sona Nanotech
5.69 SpeeDx
5.70 T2 Biosystems
5.71 Thermo Fisher Scientific Inc
5.72 Veramarx
5.73 Veredus Laboratories
5.74 Vir
5.75 XCR Diagnostics


6 Market Trends
6.1 Factors Driving Growth
6.1.1 New Genotypes Creating New Markets
6.1.2 Aging Population a Boon for All Diagnostics
6.1.3 Developing World Driving ID Dx Growth
6.1.4 Point of Care - Why Centralization is Losing Steam
6.1.5 Self Testing
6.1.6 The Need for Speed
6.1.7 The COVID Pandemic
6.2 Factors Limiting Growth
6.2.1 Lower Costs
6.2.2 Infectious Disease is Declining
6.2.3 Wellness Hurts
6.2.4 Economic Growth improves Living Standards
6.3 Instrumentation and Automation
6.3.1 Instruments Key to Market Share
6.3.2 The Shrinking Machine
6.3.3 Multiplex, Point of Care and The Speed Factor
6.4 Diagnostic Technology Development
6.4.1 The Sepsis Testing Market - A New Direction?
6.4.2 POCT/Self Testing as a Disruptive Force
6.4.3 The Genetics Play - One Test for All Known Infections
6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics


7 Molecular Dx - Infectious Disease Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.2 Home Test Company Prenetics to go Public
7.3 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
7.4 Lucira Health Posts Revenue Growth on OTC C19 Test
7.5 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
7.6 Talis Biomedical Discusses Point-of-Care
7.7 Roche to Acquire GenMark Diagnostics for $1.8B
7.8 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
7.9 Hologic to Acquire Mobidiag
7.10 Lucira Health Focuses on User Friendly Approach to Home Testing
7.11 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
7.12 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
7.13 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
7.14 Mammoth Biosciences Developing Pathogen Detection Tech
7.15 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
7.16 Scanogen Developing 90 Minute Infection Test
7.17 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
7.18 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
7.19 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
7.20 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
7.21 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
7.22 Lumos Diagnostics Closes $15M Series A Funding
7.23 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
7.24 New Genomic Tests Diagnose Deadly Infections Faster
7.25 Biotia Raises $2.4M Seed Round
7.26 STDs resurge in US
7.27 Ares Genetics signs R&D agreement with leading global IVD corporation
7.28 Cell-Free DNA Used for Infectious Disease Testing
7.29 One BioMed Raises $5M


8 The Global Market for Molecular Diagnostics at the Point of Care
8.1 Global Market Overview by Country
8.1.1 Table - Global Market by Country
8.1.2 Chart - Global Market by Country
8.2 Global Market by Application - Overview
8.2.1 Table - Global Market by Application
8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
8.2.3 Chart - Global Market by Application - Base Year
8.2.4 Chart - Global Market by Application - End Year
8.2.5 Chart - Global Market by Application - Share by Year
8.2.6 Chart - Global Market by Application - Segments Growth
8.3 Global Market by Technology - Overview
8.3.1 Table - Global Market by Technology
8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
8.3.3 Chart - Global Market by Technology - Base Year
8.3.4 Chart - Global Market by Technology - End Year
8.3.5 Chart - Global Market by Technology - Share by Year
8.3.6 Chart - Global Market by Technology - Segments Growth
8.4 Global Market by Place - Overview
8.4.1 Table - Global Market by Place
8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
8.4.3 Chart - Global Market by Place - Base Year
8.4.4 Chart - Global Market by Place - End Year
8.4.5 Chart - Global Market by Place - Share by Year
8.4.6 Chart - Global Market by Place - Segments Growth
8.5 Global Market by Product - Overview
8.5.1 Table - Global Market by Product
8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
8.5.3 Chart - Global Market by Product - Base Year
8.5.4 Chart - Global Market by Product - End Year
8.5.5 Chart - Global Market by Product - Share by Year
8.5.6 Chart - Global Market by Product - Segments Growth


9 Global MDx at the Point of Care Markets - By Application
9.1 COVID-19
9.1.1 Table COVID-19 - by Country
9.1.2 Chart - COVID-19 Growth
9.2 Respiratory Infectious Disease
9.2.1 Table Respiratory Infectious Disease - by Country
9.2.2 Chart - Respiratory Infectious Disease Growth
9.3 Gastrointestinal Infectious Disease
9.3.1 Table Gastrointestinal Infectious Disease - by Country
9.3.2 Chart - Gastrointestinal Infectious Disease Growth
9.4 Sexually Transmitted Disease
9.4.1 Table Sexually Transmitted Disease - by Country
9.4.2 Chart - Sexually Transmitted Disease Growth
9.5 Other Application
9.5.1 Table Other Application - by Country
9.5.2 Chart - Other Application Growth


10 Global MDx Markets at the Point of Care - by Technology
10.1 PCR
10.1.1 Table PCR - by Country
10.1.2 Chart - PCR Growth
10.2 NGS/Probe
10.2.1 Table NGS/Probe - by Country
10.2.2 Chart - NGS/Probe Growth
10.3 Other Technology
10.3.1 Table Other Technology - by Country
10.3.2 Chart - Other Technology Growth


11 Global MDx at the Point of Care Markets - by Place
11.1 Hospital Point of Care
11.1.1 Table Hospital Point of Care - by Country
11.1.2 Chart - Hospital Point of Care Growth
11.2 Clinic or Physician Office Lab
11.2.1 Table Clinic or Physician Office Lab - by Country
11.2.2 Chart - Clinic or Physician Office Lab Growth
11.3 Seniors Facility
11.3.1 Table Seniors Facility - by Country
11.3.2 Chart - Seniors Facility Growth
11.4 Other Place
11.4.1 Table Other Place- by Country
11.4.2 Chart - Other Place Growth


12 Global MDx at the Point of Care Markets - by Product
12.1 Instrument
12.1.1 Table Instrument - by Country
12.1.2 Chart - Instrument Growth
12.2 Cartridge
12.2.1 Table Cartridge - by Country
12.2.2 Chart - Cartridge Growth
12.3 Other Product
12.3.1 Table Other Product - by Country
12.3.2 Chart - Other Product Growth


13 Appendices
13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule


List of Tables
Table 1 Classification of HIV Species
Table 2 HIV Tests - CMS Codes & Prices
Table 3 Current HIV Molecular Tests and Instruments Used
Table 4 HBV Tests - CMS Codes & Prices
Table 5 HCV Tests - CMS Codes & Prices
Table 6 HPV Clearance Rates
Table 7 HPV Tests - CMS Codes & Prices
Table 8 HPV Tests, Technology, Types
Table 9 Types of Influenza Tests
Table 10 Influenza Tests - CMS Codes & Prices
Table 11 FDA Cleared Molecular Assays for Influenza
Table 12 FDA Cleared NAAT CTGC Tests
Table 13 CTGC NAAT Target Sequences and Possible False Reactions
Table 14 CTGC Tests - CMS Codes & Prices
Table 15 FDA Approved MDx Tests for Tuberculosis
Table 16 Tuberculosis Tests - CMS Codes & Prices
Table 17 FDA Approved Tests for MRSA
Table 18 MRSA Tests - CMS Codes & Prices
Table 19 FDA Approved Tests for VRE
Table 20 VRE Tests - CMS Codes & Prices
Table 21 FDA Approved Multiplex Assays
Table 22 Characteristics of Coronavirus Pandemic Infections
Table 23 COVID-19 Symptoms
Table 24 Market Players by Type
Table 25 Clinical Laboratory Departments and Segments
Table 26 Laboratory Management Focus - Different Approaches
Table 27 Key Segmentation Variables Going Forward
Table 28 Five Factors Driving Growth
Table 29 Four Factors Limiting Growth
Table 30 Key Diagnostic Laboratory Technology Trends
Table 31 - Global Market by Region
Table 32 Global Market by Application
Table 33 Global Market by Technology
Table 34 Global Market by Place
Table 35 Global Market by Product
Table 36 COVID-19 by Country
Table 37 Respiratory Infectious Disease by Country
Table 38 Gastrointestinal Infectious Disease by Country
Table 39 Sexually Transmitted Disease by Country
Table 40 Other Application by Country
Table 41 PCR by Country
Table 42 NGS/Probe by Country
Table 43 Other Technology by Country
Table 44 Hospital Point of Care by Country
Table 45 Clinic or Physician Office Lab by Country
Table 46 Seniors Facility by Country
Table 47 Other Place by Country
Table 48 Instrument by Country
Table 49 Cartridge by Country
Table 50 Other Product by Country
Table 51 2021 Clinical Lab Fee Schedule


List of Figures
Figure 1 Map - Global Healthcare Spending Per Capita
Figure 2 The Lab Test Pie - Wholesale vs. Retail
Figure 3 HIV Virion
Figure 4 Diagram of the HIV Replication Cycle
Figure 5 The Structure of the HBV Virus
Figure 6 Hepatitis B Replication
Figure 7 Structure of the HCV Virus
Figure 8 HCV Replication Cycle
Figure 9 Structure of the Influenza Virion
Figure 10 Influenza Replication
Figure 11 Scanning Electron micrograph of Tuberculosis
Figure 12 Percentage of World Population Over 65
Figure 13 Chart Infectious Disease Decline
Figure 14 Global Market Shares Chart
Figure 15 Global Market by Application - Base vs. Final
Figure 16 Global Market by Application Base Year
Figure 17 Global Market by Application End Year
Figure 18 Application Share by Year
Figure 19 Application Segments Growth
Figure 20 Global Market by Technology - Base vs. Final
Figure 21 Global Market by Technology Base Year
Figure 22 Global Market by Technology End Year
Figure 23 Technology Share by Year
Figure 24 Technology Segments Growth
Figure 25 Global Market by Place - Base vs. Final
Figure 26 Global Market by Place Base Year
Figure 27 Global Market by Place End Year
Figure 28 Place Share by Year
Figure 29 Place Segments Growth
Figure 30 Global Market by Product - Base vs. Final
Figure 31 Global Market by Product Base Year
Figure 32 Global Market by Product End Year
Figure 33 Product Share by Year
Figure 34 Product Segments Growth
Figure 35 COVID-19 Growth
Figure 36 Other Infectious Disease Diagnostics Growth
Figure 37 Gastrointestinal Infectious Disease Growth
Figure 38 Sexually Transmitted Disease Growth
Figure 39 Other Application Growth
Figure 40 PCR Growth
Figure 41 NGS/Probe Growth
Figure 42 Other Technology Growth
Figure 43 Hospital Point of Care Growth
Figure 44 Clinic or Physician Office Lab Growth
Figure 45 Seniors Facility Growth
Figure 46 Other Place Growth
Figure 47 Instrument Growth
Figure 48 Cartridge Growth
Figure 49 Other Product Growth


Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Bio-Rad Laboratories, Inc
  • Biocartis
  • bioMérieux Diagnostics
  • Bosch Healthcare Solutions GmbH
  • Cepheid (now Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A
  • Eiken Chemical
  • Enzo Life Sciences, Inc
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics
  • Genedrive
  • Genetic Signatures
  • GenMark Dx
  • Grifols
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech
  • Millipore Sigma
  • Mindray
  • Mobidiag
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Primerdesign
  • Prominex
  • Qiagen Gmbh
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher Scientific Inc
  • Veramarx
  • Veredus Laboratories
  • Vir
  • XCR Diagnostics
Note: Product cover images may vary from those shown

Loading
LOADING...